8-K - REGENEREX PHARMA, INC. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Regenerex Pharma, Inc. placed CFO Kenneth Perry on paid administrative suspension leave effective March 31, 2026, due to compliance and governance concerns, and appointed Don E. Ray as Interim CFO effective April 1, 2026.

Key Takeaways

1Board placed CFO Kenneth Perry on paid administrative suspension leave effective March 31, 2026, removing his duties pending review.

2Concerns include compliance with Board directives, financial oversight, corporate governance, financial reporting, and internal controls.

3Don E. Ray appointed Interim CFO effective April 1, 2026, with 90-day initial term and $150,000 annual salary.

4Perry remains employee receiving base salary and benefits during suspension.

5Review of matters is ongoing with no final determinations made.

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events

Other Event

Executive & Director Changes

Kenneth Perry

Chief Financial Officer

Placed on administrative suspension leave with pay; duties removed and reassigned

Effective: 2026-03-31

Concerns relating to compliance with Board directives, financial oversight, corporate governance, financial reporting processes and internal controls; matters under review

Don E. Ray

Interim Chief Financial Officer

Appointed

Effective: 2026-04-01

Exhibits (1)

8-K

CURRENT REPORT